- Home
- CWD vs KZIA Comparison
CWD vs KZIA Comparison
Compare CWD & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- KZIA
- Stock Information
- Founded
- CWD 2009
- KZIA 1994
- Country
- CWD United States
- KZIA Australia
- Employees
- CWD N/A
- KZIA N/A
- Industry
- CWD Real Estate
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- CWD Finance
- KZIA Health Care
- Exchange
- CWD Nasdaq
- KZIA Nasdaq
- Market Cap
- CWD 4.7M
- KZIA 5.1M
- IPO Year
- CWD 2023
- KZIA 1999
- Fundamental
- Price
- CWD $3.54
- KZIA $6.10
- Analyst Decision
- CWD
- KZIA Strong Buy
- Analyst Count
- CWD 0
- KZIA 2
- Target Price
- CWD N/A
- KZIA $57.50
- AVG Volume (30 Days)
- CWD 18.6K
- KZIA 2.6M
- Earning Date
- CWD 08-11-2025
- KZIA 07-07-2025
- Dividend Yield
- CWD N/A
- KZIA N/A
- EPS Growth
- CWD N/A
- KZIA N/A
- EPS
- CWD N/A
- KZIA N/A
- Revenue
- CWD $35,429,000.00
- KZIA $1,549,158.00
- Revenue This Year
- CWD N/A
- KZIA N/A
- Revenue Next Year
- CWD $31.12
- KZIA N/A
- P/E Ratio
- CWD N/A
- KZIA N/A
- Revenue Growth
- CWD N/A
- KZIA 248983.08
- 52 Week Low
- CWD $3.00
- KZIA $2.86
- 52 Week High
- CWD $18.40
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- CWD 44.15
- KZIA 50.96
- Support Level
- CWD $3.18
- KZIA $5.83
- Resistance Level
- CWD $3.90
- KZIA $9.60
- Average True Range (ATR)
- CWD 0.39
- KZIA 1.19
- MACD
- CWD 0.07
- KZIA -0.29
- Stochastic Oscillator
- CWD 30.77
- KZIA 18.39
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.